Our top pick for
CorMedix Inc is a biotechnology business based in the US. CorMedix shares (CRMD) are listed on the NASDAQ and all prices are listed in US Dollars. CorMedix employs 35 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.76|
|52-week range||$4.36 - $17.93|
|50-day moving average||$5.02|
|200-day moving average||$6.76|
|Wall St. target price||$21.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.72|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-4.42%|
|1 month (2021-09-21)||3.25%|
|3 months (2021-07-21)||-28.10%|
|6 months (2021-04-21)||-39.97%|
|1 year (2020-10-20)||-16.78%|
|2 years (2019-10-18)||-21.84%|
|3 years (2018-10-19)||286.99%|
|5 years (2016-10-20)||110.62%|
|Gross profit TTM||$34,385|
|Return on assets TTM||-30.66%|
|Return on equity TTM||-51.45%|
|Market capitalisation||$188.5 million|
TTM: trailing 12 months
There are currently 2.0 million CorMedix shares held short by investors – that's known as CorMedix's "short interest". This figure is 3.4% down from 2.0 million last month.
There are a few different ways that this level of interest in shorting CorMedix shares can be evaluated.
CorMedix's "short interest ratio" (SIR) is the quantity of CorMedix shares currently shorted divided by the average quantity of CorMedix shares traded daily (recently around 300164.27480916). CorMedix's SIR currently stands at 6.55. In other words for every 100,000 CorMedix shares traded daily on the market, roughly 6550 shares are currently held short.
However CorMedix's short interest can also be evaluated against the total number of CorMedix shares, or, against the total number of tradable CorMedix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CorMedix's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 CorMedix shares in existence, roughly 50 shares are currently held short) or 0.0523% of the tradable shares (for every 100,000 tradable CorMedix shares, roughly 52 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CorMedix.
Find out more about how you can short CorMedix stock.
We're not expecting CorMedix to pay a dividend over the next 12 months.
CorMedix's shares were split on a 1:5 basis on 25 March 2019. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CorMedix shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for CorMedix shares which in turn could have impacted CorMedix's share price.
Over the last 12 months, CorMedix's shares have ranged in value from as little as $4.36 up to $17.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CorMedix's is 2.5254. This would suggest that CorMedix's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CorMedix Inc. , a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.